US2019365890A1PendingUtilityA1

A B Cell Depleting Agent for the Treatment of Atherosclerosis

Assignee: MALLAT ZIADPriority: Jan 6, 2009Filed: Jul 9, 2019Published: Dec 5, 2019

Est. expiryJan 6, 2029(~2.4 yrs left)· nominal 20-yr term from priority

Inventors:Ziad Mallat Hafid Ait-Oufella Alain Tedgui Thomas F. Tedder

A61P 9/10A61P 9/00C07K 16/244A61K 2039/505A61K 47/6849C07K 2317/24C07K 16/2887A61K 39/3955

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.

Claims

exact text as granted — not AI-modified

1 . A method for treating myocardial infarction in a subject in need thereof, comprising the step of
 administering a sufficient quantity of an anti-human CD20 antibody to said subject within one hour of the myocardial infarction, wherein said anti-human CD20 antibody depletes or destroys mature B cells or interferes with B cell functions in said subject and increases fractional shortening.   
     
     
         2 . The method of  claim 1 , wherein said anti-human CD20 antibody is a full length anti-CD20 antibody. 
     
     
         3 . The method of  claim 1 , wherein the myocardial infarction is a ST segment elevation myocardial infarction.

Join the waitlist — get patent alerts

Track US2019365890A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.